Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
BofA Securities Maintains Ardent Health Partners(ARDT.US) With Hold Rating, Maintains Target Price $19
Mizuho Securities Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Mizuho Securities Keeps Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Press Release: Ardent Health Reports Third Quarter 2024 Results
Express News | Ardent Health Raises FY24 Revenue To $5.8B-$5.875B From $5.75B-$5.9B; Updates Diluted EPS To $1.18-$1.32 From $1.23-$1.37
